Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Venus Medtech (Hangzhou)'s Enterprise Value is HK$269.0 Mil.
Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-426.1 Mil. Therefore, Venus Medtech (Hangzhou)'s EV-to-EBIT ratio for today is -0.63.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Venus Medtech (Hangzhou) (HKSE:02500) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Venus Medtech (Hangzhou)'s EV-to-EBIT for today is
Venus Medtech (Hangzhou)'s current Enterprise Value is HK$269.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-426.1 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Venus Medtech (Hangzhou)'s EV-to-EBITDA for today is:
Venus Medtech (Hangzhou)'s current Enterprise Value is HK$269.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-319.1 Mil.
Venus Medtech (Hangzhou)'s current Enterprise Value is HK$269.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$336.7 Mil.
Venus Medtech (Hangzhou)'s current Enterprise Value is HK$269.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-353.7 Mil.
Venus Medtech (Hangzhou)'s current Enterprise Value is HK$269.0 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-365.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) Enterprise Value Related Terms
Venus Medtech (Hangzhou) Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02500 vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Enterprise Value distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Enterprise Value falls into.
Venus Medtech (Hangzhou) Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Venus Medtech (Hangzhou)'s Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$269.0 Mil mean?
Venus Medtech (Hangzhou) (HKSE:02500) has a Enterprise Value of HK$269.0 Mil as of Aug. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Venus Medtech (Hangzhou) and its competitors.
Is Venus Medtech (Hangzhou)'s Enterprise Value too high?
Venus Medtech (Hangzhou)'s current Enterprise Value is HK$269.0 Mil. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Enterprise Value compare to ABT and SYK?
Venus Medtech (Hangzhou)'s Enterprise Value of HK$269.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current Enterprise Value is HK$269.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.35, compared to a current price of HK$1.10 — trading 67.2% below its estimated fair value. The current Enterprise Value is HK$269.0 Mil. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current Enterprise Value is HK$269.0 Mil as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of HK$1.10 is trading 67.2% below its estimated GF Value™ of HK$3.35.
GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.
Key valuation signals for HKSE:02500:
Enterprise Value: HK$269.0 Mil
GF Value™: HK$3.35 vs. price of HK$1.10 (67.2% below fair value)
No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for HKSE:02500
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02500 has been successfully added to your 
